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Abstract:  The main objective of the presented study was the development of a simple 
analytical  tool  for  exploring  the  influence  of  naturally  occurring  compounds  on  the 
aggregation of amyloid-β peptide (Aβ40) in order to find potential anti-neurodegenerative 
drugs.  The  gold  discs  used  for  surface  plasmon  resonance  (SPR)  measurements  were 
modified with thioaliphatic acid. The surface functionalized with carboxylic groups was 
used for covalent attaching of Aβ40 probe by creation of amide bonds in the presence of 
EDC/NHS. The modified SPR gold discs were used for exploring the Aβ40 aggregation 
process in the presence of selected alkaloids: arecoline hydrobromide, pseudopelletierine 
hydrochloride,  trigonelline  hydrochloride  and  α-lobeline  hydrochloride.  The  obtained 
results were discussed with other parameters which govern the phenomenon studied such 
as lipophilicity/ hydrophilicy and Aβ40-alkaloid association constants. 
Keywords:  amyloid-β peptide; surface plasmon resonance; alkaloids; thioaliphatic acid 
monolayer 
 
1. Introduction 
Abnormal folding and aggregation of proteins characterizes many, if not all, neurodegenerative 
disorders  such  as  Alzheimer’s  (AD),  Parkinson’s,  Creutzfeldt-Jakob  disease  and  large  group  of 
poliglutamine disorders including Huntington’s disease [1]. Aggregation of Amyloid-β peptide (Aβ) 
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from its soluble monomers into insoluble well-ordered amyloid fibrils has been assumed to be a key 
molecular hallmark in the pathology of Alzheimer’s disease (AD) [2,3]. In a nucleation-dependent 
polymerization  model  Aβ40  aggregation  consists  of  two  phases:  thermodynamically  unfavourable 
nuclei  formation,  followed  by  their  spontaneous  elongation  and  growth.  Soluble  α-helical  or  
random-coil structures can convert into β-sheet protofibrilar intermediates which act as a seed for 
amyloid formation and plaque precipitation [4,5]. Formation of soluble β-sheet oligomers has been 
reported to be essential for neurodegeneration processes and is suspected to play a principal role in the  
Aβ-mediated toxicity [6]. Thus targeting of α-helical and random-coil structures’ transition to β-sheeted 
species could provide AD prevention and treatment or retard the onset of disease. Among other modes 
of  action,  direct  targeting  Aβ  misfolding  and  aggregation  phenomenon  might  be  one  of  the most 
promising therapeutic methods against AD disease.  
Numerous plant-derived molecules have been tested in vitro and in vivo but special attention has 
been reserved for the alkaloid nicotine and its derivatives, as they are well known to exert an influence 
on  cognitive  functions  [7].  While  it  seems  that  first  of  all  the  multiple  influence  of  nicotine  on 
cholinergic  transmission  is  responsible  for  its  beneficial  effects  on  AD  patients  [8-10],  there  are  
in  vitro  studies  suggesting  that  this  alkaloid  can  alter  Aamyloidogenesis  directly  [11-14].  The 
associations  of  aggregated  Aβ40  with  nicotine  and  cotinine  as  well  as  the  other  pyridine-  and  
piperdine-derived alkaloids were determined electrochemically [15,16]. Since Aβ is a target molecule 
in many AD therapies, compounds revealing significant affinity towards this peptide could also serve 
as effective Aβ oligomerization and neurotoxicity inhibitors and have to be taken into consideration as 
possible anti-AD drugs. 
Surface  plasmon  resonance  (SPR)  spectroscopy  has  been  successfully  employed  in  studies 
concerning molecular interactions associated with different amyloidoses [17]. Various aspects of A 
oligomerization, fibril growth, dissociation as well as A binding to biomolecules were examined with 
SPR [18]. The in vitro anti-amyloidogenic activity of metal ions chelators, short peptides, antibody 
fragments and flavonoids has been tested utilizing SPR-based methods [19-23]. In most SPR-based 
biosensors applied for study of Aβ aggregation as well as its interactions with aggregation inhibitors, 
carboxymethyldextran was used as the interaction platform [20-24].  
In the present study we proposed a simple in preparation SPR biosensor based on a thioaliphatic 
acid self-assembled monolayer (SAM) formed on gold SPR disc. The attachment of Aβ40 peptide 
probe to the carboxyl-terminated surface was performed via amide bond formation. 
The  proposed  biosensor  was  applied  for  in  situ  monitoring  of  Aβ40  early  aggregation  stages 
(oligomerization)  in  the  presence  of  potential  aggregation  inhibitors.  The  influence  of  arecoline,  
α-lobeline, trigonelline and pseudopelletierine (Figure 1(B)) on Aβ40 aggregation was examined. These 
compounds  derived  from  domestic  plants  are  either  commonly  used  as  psychoactive  substances 
(arecoline  and  α-lobeline)  or  are  consumed  as  a  dietary  component  (trigonelline  and 
pseudopelletierine). Plants and products containing the considered alkaloids are easily available, which 
creates the possibility of using them (or their derivatives) as a diet supplementation in AD prevention 
and treatment. For comparison, one pharmacologically unrelated compound, pyridoxine (vitamin B6) 
was tested too.  Sensors 2011, 11                                       
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Figure 1. Amyloid β peptide (1–40) amino acid sequence (A) and chemical structure of 
tested compounds (B). 
 
2. Experimental Section  
2.1. Chemicals 
Amyloid  β  protein  (1–40),  trifluoroacetate  salt  Aβ40  was  purchased  from  Bachem,  Switzerland  
(lot 1020370). Ammonium hydroxide, 11-mercaptoundecanoic acid (11-MUA), trifluoroacetic acid,  
2-morpholinoethanesulfonic acid (MES), N-hydroxysuccinimide (NHS), N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide  hydrochloride  (EDC),  ethanolamine,  pyridoxine,  arecoline  hydrobromide, 
pseudopelletierine  hydrochloride,  trigonelline  hydrochloride,  α-lobeline  hydrochloride  and  PBS 
components: sodium chloride, potassium chloride, sodium phosphate dibasic, potassium phosphate 
monobasic were supplied by Sigma-Aldrich, Poznań, Poland. Ethanol absolute, hydrochloric acid and 
sodium hydroxide were obtained from POCH, Poland. Reagents and solvents were of analytical grade 
and used without any purification step. All aqueous solutions were prepared using autoclaved Milli-Q 
water, resistivity 18.2 MΩ· cm (Millipore Corporation, USA). All buffers used for SPR experiments 
were rigorously filtrated through 0.22 µ m sterile PVDF filters (Roth, Germany). 
2.2. Surface Plasmon Resonance Apparatus 
An Autolab Springle SPR system (Eco Chemie, The Netherlands) equipped with a thermostatic 
water bath (Julabo Labortechnik, Germany) was used. Springle SPR was employed for monitoring 
both Aβ40 probe immobilization and Aβ40 aggregation. The experiments were carried out continuously 
and the immobilization step was followed by aggregation procedure, as described below. Sensors 2011, 11                                       
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2.3. Peptide Preparation  
The  lyophilized  synthetic  Aβ40  peptides  were  dissolved  in  0.02%  ammonia  solution  at  the 
concentration of 300 µ M by brief vortexing. Then the solution was sonicated for 2 min in a water bath 
at 4 ° C. The Aβ40 aliquots were stored in at −85 ° C.  
2.4. Formation of 11-MUA SAM 
Gold-coated SPR discs were supplied by Eco Chemie, The Netherlands. Prior to modification, discs 
were rinsed with Milli-Q water then with ethanol and dried thoroughly in a stream of nitrogen. Gold 
discs were treated with UV-ozone chamber (Novascan, USA) for 20 min in order to remove any 
organic contaminations. Clean gold SPR discs were immediately immersed for 30 min in 1.0 mM 
solution of 11-MUA in ethanol containing 2% of trifluoroacetic acid. Afterwards discs were rinsed 
with ethanol, 10% solution of ammonia in ethanol, again with ethanol and gently dried in a stream of 
nitrogen before placing in SPR chamber. Formation of 11-MUA SAM was carried out according to 
modified method described by Wang et al. [25].  
2.5. Immobilization Aβ40 Peptide Probe 
Probe immobilization was performed at 22 ° C using 50 mM MES (pH 5.5) as running buffer. 
Freshly 11-MUA-modified discs were placed in the SPR chamber and conditioned in running buffer 
for 2 h. Every 30 min discs were washed with 4 mL of running buffer. After conditioning, when stable 
readout was achieved, the carboxyl groups of 11-MUA SAM were activated by treating with a mixture 
of 100 mM EDC and 50 mM NHS in 50 mM MES (pH 5.5) for 15 min. Subsequently discs were 
washed with 2 mL of running buffer and the value of SPR angle shift was recorded after 3 min. Aβ40 
aliquots  were  diluted  with  50  mM  MES  (pH  6.5)  to  30µ M,  briefly  vortexed  and  injected  on  the 
activated disc surface. After 20-min incubation peptide solution was rinsed off with 2 mL of running 
buffer  and  followed  by  quenching  the  remaining  NHS-activated  sites  with  1.0  M  ethanolamine  
in 50 mM MES (pH 8.5) for 10 min. Finally, discs were rinsed with 4 mL of the running buffer and the 
value of SPR angle shift was recorded 10 min after the end wash.  
2.6. Aβ40 Aggregations 
Aggregation experiments were performed at 37 ° C using 10 mM PBS (pH 7.4) as running buffer. 
Prior to the experiment, discs with immobilized probe were washed with 4 mL of running buffer and 
conditioned until the stable readout was gained. SPR angle shift values were recorded after 1 h of 
conditioning.  Aβ40  aliquots  were  diluted  within  PBS  to  30  µ M.  1.0  mM  alkaloids:  arecoline, 
pseudopelletierine, trigonelline and α-lobeline as well as pyridoxine were dissolved in PBS. Final pH 
was adjusted to 7.4 ± 0.05. Then discs were incubated in a solution of Aβ40 with a supplementation of 
selected alkaloid for 2 h followed by washing with 4 mL of running buffer. The same experiment, but 
without tested compounds has been preformed too (control aggregation). Values of SPR shift angle 
were recorded 20 min after the end wash. Sensors 2011, 11                                       
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2.7. Aggregation of Aβ40 Peptide on the Surface of 11-MUA SAM Treated with Ethanolamine after 
Activation with EDC/NHS (Background Aggregation)  
Freshly 11-MUA-modified discs were placed in SPR chamber and conditioned in 50 mM MES  
(pH 5.5) running buffer for 2 h. Every 30 min discs were washed with 4 mL of running buffer. After 
conditioning, when stable readout was achieved, the carboxyl groups of 11-MUA SAM were activated 
by treating with a mixture of 100 mM EDC and 50 mM NHS in 50 mM MES (pH 5.5) for 15 min. 
Subsequently discs were washed with 2 mL of running buffer and the value of SPR angle shift was 
recorded after 3 min. Instead of diluted Aβ40 peptide, a solution containing 50 mM MES (pH 5.5)  
with 0.002% ammonia only was injected, incubated for 20-min and rinsed off with 2 mL of running 
buffer. This was followed by quenching the remaining NHS-activated sites with 1.0 M ethanolamine  
in 50 mM MES (pH 8.5) for 10 min. Finally, discs were rinsed with 4 ml of the running buffer and the 
value of SPR angle shift was recorded 10 min after the end wash. Aggregation was performed at 37 ° C 
using 10 mM PBS (pH 7.4) as running buffer. Prior to the experiment, discs were washed with 4 mL of 
running  buffer  and  conditioned  until  the  stable  readout  was  gained.  SPR  angle  shift  values  were 
recorded after 1 h of conditioning. Then discs were incubated in a solution of 30 µ M Aβ40 in PBS  
for  2  h  followed  by  washing  with  4  mL  of  running  buffer.  Values  of  SPR  shift  angle  were  
recorded 20 min after the end wash. 
2.8. Influence of Tested Alkaloids on SPR Angle Shift of Aβ40-Funcionalized Disc. 
Experiments were performed at 37 ° C using 10 mM PBS (pH 7.4) as running buffer. Prior to the 
experiment, discs with immobilized probe were washed with 4 mL of running buffer and conditioned 
until  the  stable  readout  was  gained.  SPR  angle  shift  values  were  recorded  after  1  h  of  
conditioning. 1.0 mM alkaloids: arecoline, pseudopelletierine, trigonelline and α-lobeline as well as 
pyridoxine  were  dissolved  in  PBS  containing  0.002%  ammonia  solution.  Final  pH  was  adjusted  
to 7.4 ±  0.05. Then discs were incubated in alkaloid solution for 2 h followed by washing with 4 mL of 
running buffer. Values of SPR shift angle were recorded 20 min after the end wash. 
2.9. Data Presentation and Statistical Analysis 
Aggregation assay results were presented as means ±  standard deviation for at least five replicates 
for each experimental group. Results were submitted to the t-test (The Analysis ToolPak, Microsoft, 
USA) and values of p < 0.05 were considered as statistically significant. 
3. Results and Discussion  
The 11-MUA-modified SPR gold discs were utilized for the covalent binding of Aβ40 peptide probe. 
The  immobilization  procedure  scheme  is  shown  in  Figure  2.  The  immobilization  of  Aβ40  peptide 
probe, performed via EDC/NHS coupling chemistry [26], was monitored constantly and the SPR angle 
shift was recorded. The representative binding curve was illustrated in Figure 3. The probe-immobilizing 
procedure resulted in around 0.55 ±  0.12 ng of Aβ40 peptide attached per 1 mm
2 of disc surface.  Sensors 2011, 11                                       
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Figure 2. Scheme of Aβ40 probe immobilization on 11-MUA-modified surface of SPR gold 
disc (A–C) and Aβ40 aggregation assay on Aβ40-functionalized gold discs surface (D–E).  
 
Figure 3. SPR binding curve for Aβ40 immobilization on 11-MUA-SAM modified gold 
disc (For measurement details, see Experimental part 2.5).  
 
 
In order to check if the proposed biosensor is able to detect the early steps of the aggregation 
process, two series of control aggregations were carried out. In first, the Aβ40 solution was injected on 
the surface of Aβ40 functionalized disc (control aggregation), and in second, the same solution was 
injected on the disk surface modified only with 11-MUA SAM, which was treated with ethanolamine 
after activation with EDC/NHS (background aggregation). The value of SPR angle shifts for control 
aggregation was 125.7 ±  15.6 m°  and for background only 60.1 ±  3.6 m°  (Figure 4(A)). This indicated 
that the rate of specific deposition of Aβ40 on surface modified with Aβ40-probe was ca. 50% higher Sensors 2011, 11                                       
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than non-specific background deposition of Aβ40 on the ethanolamine deactivated 11-MUA SAM. The 
phenomenon of beta-amyloid aggregation on the surface of SAMs with different functional groups 
(without Aβ40-probe) was reported in the literature [27]. The authors concluded that SAMs induced 
aggregation  of  Aβ.  The  hybrophobicity  /hydrophilicy  of  functional  groups  present  on  the  SAMs’ 
surface  is  the  main  factor  which  governs  this  phenomenon.  Molecular  docking  and  dynamics 
simulations have been applied for exploring the conformational changes and adsorption behaviour of 
Aβ  monomer  on  various  SAMs.  The  hydrophobic  CH3-SAM  has  a  lower  energy  barrier  for  Aβ 
monomer adsorption than OH-SAM [28]. For the COOH-SAM and NH2-SAM bearing relatively large 
charge in the head groups, electrostatic interactions between Aβ and SAMs provide the additional 
driving force for Aβ adsorption [29]. The background Aβ aggregation was performed on the 11-MUA 
SAM, treated with ethanolamine after activation with EDC/NHS. Thus, on this surface the OH groups 
are dominant. Only a few COOH could be present, so Aβ monomer adsorption on such SAM is driven 
by very weak Aβ-SAM interactions with strong SAM-water interactions which results in a net weak 
affinity of Aβ adsorption on OH-SAM [29]. Prior to aggregation assays with alkaloids and pyridoxine, 
possible  interactions  between  those  compounds  and  the  Aβ40-functionalized  SPR  gold  disc  were 
checked. Incubations of probe-modified discs with the tested alkaloids injected alone onto disc surface 
revealed that SPR angle shifts were negligible (−0.8 m°  for arecoline, −0.6 m° for α-lobeline, 0.5 m°  
for pseudopelletierine, −0.3 m°  for trigonelline and 0.5 m°  for pyridoxine). Thus, the proposed assay 
was deemed selective and suitable for performing the Aβ40 aggregation processes in the presence of  
selected compounds.  
Figure 4(B–E) shows the representative binding curves for incubation of Aβ40-probe-functionalized 
gold discs with Aβ40 solution containing 1.0 mM of tested alkaloid. For comparison the representative 
binding  curve  for  incubation  of  Aβ40-probe-functionalized  disc  with  Aβ40  solution  without  any 
additives (control aggregation) was included.  
Figure 4. The representative SPR binding curves for Aβ40 aggregations. (A) Aggregations 
of Aβ40 injected alone performed on SPR gold discs surface functionalized with: Aβ40 
probe  (control)  or  with  11-MUA SAM treated  with  ethanolamine  after activation with 
EDC/NHS (background); (B–F) Aggregations of Aβ40 injected alone (control) or in the 
presence of 1.0 mM of tested compound performed on a Aβ40-functionalized gold discs 
surface (For measurement conditions-see Experimental parts: 2.6 and 2.7). 
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Figure 4. Cont. 
 
 
 
The  addition  of  α-lobeline  and  arecoline  to  the  assay  significantly  (p  <  0.01)  decreased  Aβ40 
aggregation. Values of SPR angle shifts decreased from 125.7 ± 15.6 m° for control incubation (Aβ40 
injected  alone)  to  83.1  ±   16.5  m°   for  arecoline  (Figure  4(B))  and  74.8  ±   23.8  m°   for  α-lobeline 
supplementation  (Figure  4(C)).  On  the  contrary,  addition  of  pseudopelletierine  to  the  aggregation 
assay showed a tendency to elevate SPR angle shift to 164.5 ±  14.1 m°  (Figure 4(D)). Trigonelline did 
not affect Aβ40 peptide deposition and SPR angle shift resulted in 121.9 ±  25.6 m°  (Figure 4(E)). 
Aggregation assay with addition of pharmaceutically unrelated compound, pyridoxine (vitamin B6), 
did not influence Aβ40 deposition (122.5 ±  14.4 m° ; Figure 4(F)).  
Figure  5. SPR angle shift values for Aβ40 aggregation on an Aβ40-functionalized gold 
discs. Measurement conditions: see Experimental part 2.6; values are significantly different  
(P < 0.01); N = 5. 
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The values of SPR angle shift was recorded 20 min after the final wash. Aβ40 deposition obtained 
for  incubations  with  tested  compounds  was  calculated  relative  to  the  aggregation  control  (100%) 
(Figure 5).  
In our previous study, association constants for Aβ40 peptide and selected alkaloids were established 
electrochemically [16]. The highest affinity to the Aβ40 was determined for arecoline: 2.30 ×  10
8 M
−1. 
The  association  constant  for  α-lobeline  was  equal  to  0.90  ×   10
8  M
−1,  while  binding  of 
pseudopelletierine (0.57 ×  10
8 M
−1) and trigonelline (0.28 ×  10
8 M
−1) were relatively weaker [16]. In 
the present study, only two alkaloids: α-lobeline and arecoline, were shown to be potential inhibitors 
of early Aβ40 aggregation and their therapeutic and/or prophylactic significance can be suggested.  
The phenomenon of interaction between examined compounds and Aβ peptide, resulting in altered 
aggregation, can be considered as a process composed of two steps. At the first stage alkaloid passes 
through  the  water-peptide  interface,  moving  from  aqueous  phase  to  the  relatively  lipophilic 
environment consisted of Aβ molecules, either deposited on gold disc surface or remaining in the 
solution. In that case the permeability of substance is determined by its lipophilicity. This attribute also 
governs  drug  bioavailability  and  cannot  be  neglected  when  potential  therapeutic  or  prophylactic 
benefits of compound administration are considered. Thus, the lipophilicity of drug candidate is an 
important factor which enables any subsequent ligand-Aβ40 peptide interactions. The second step of 
considered  phenomenon  refers  to  the  direct  interaction  between  the  drug-and  receptor  site  in  the 
peptide. These two factors, ability to cross the interface and binding to the specific fragment of the 
peptide  can  be  crucial  for  determining  the  effects  of  alkaloid  influence  on  Aβ40  aggregation  
observed herein. 
In light of those assumptions, the lipophilicity of tested compounds was taken into account. Log D 
(pH  7.4)  values  of  the  examined  alkaloids  and  pyridoxine  were  found  in  ChemSpider  online  
database [30] and was collected in Table 1. Log D is an octanol/water partition coefficient, where the 
neutral species as well as ionized forms are considered. It is assumed to be accurate for the prediction 
of molecule hydrophilic or lipophilic behaviour under given pH [31]. The theoretical log D values 
revealed that arecoline and α-lobeline are the most lipophilic among the studied alkaloids. Their log D 
values are equal to 0.71 and 2.14 respectively. Both of them appear to be inhibitors of Aβ40 aggregation. 
Table  1.  Aβ40  aggregation  in  relation  to  control  (100%),  log  D  (pH  7.4)  values  of  
alkaloids [30] and their association constants with Aβ40 peptide [16]. 
Compound 
Aggregation 
[%]of control 
Log D 
pH 7.4 [30] 
Log Ka 
10
8 [M
−1] [16] 
Lobeline   59.1 ±  18.9  2.14  0.90  
Arecoline   66.1 ±  13.1  0.71  2.30 
Pseudopelletierine  130.9 ±  11.2  −0.96  0.57 
Trigonelline  97.0 ±  20.4  −3.31  0.28 
Pyridoxine  97.5 ±  11.4  −1.45  - 
 
The log D values of pseudopelletierine and trigonelline are −0.96 and −3.31, respectively, showing 
the  predominantly  hydrophilic  character  of  these  compounds  under  physiological  pH. 
Pseudopelletierine demonstrated similar affinity towards Aβ40 peptide as was recorded for trigonelline Sensors 2011, 11                                       
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or  α-lobeline  [16],  but  at  the  same  time,  this  compound  induced  an  acceleration  of  the  Aβ40 
aggregation process. The specific non-flat geometry of pseudopelletierine molecule (Figure 1) could 
be responsible for the observed effect. The results we have got for trigonelline indicated that the 
hydrophilicity of this compounds is a decisive parameter governing its very weak interaction with Aβ40 
peptide. Similar results were observed for pyridoxine (vitamin B6; log D = −1.45) which is known as a 
neutral compound concerning Aβ40 peptide aggregation.  
Protein aggregation processes have been  widely explored by fluorescence assays [14,21,23,32], 
circular  dichroism  spectroscopy  [11,22],  atomic  force  microscopy  [21,23,27,33]  electrochemical 
methods  [15,16,34]  as  well  as  SPR  based  biosensors  [19-24,26,35-37].  The  development  of  SPR 
techniques improved crucially the performance of bio-chemical sensing devices [38-40].  
Here, we present the simple thioaliphatic carboxylic acid monolayer deposited in the one step of 
modification on the surface of SPR gold disc. Such a simple modification was suitable for covalent 
attaching of Aβ40-peptide probe via amide bond formation. It is worth underlining that the surface of 
11-MUA SAM displayed good selectivity. The unspecific aggregation of Aβ40 was significantly lower 
in the comparison to the Aβ40 aggregation performed on the surface with Aβ40 probe covalently bound 
via amide bonds (Figure 4(A)).  
4. Conclusions  
The proposed SPR biosensor based on 11-mercaptoundecanoic acid (11-MUA) was useful for study 
of  the  influence  of  several  alkaloids—arecoline  hydrobromide,  pseudopelletierine  hydrochloride, 
trigonelline hydrochloride, α-lobeline hydrochloride—on the aggregation process of Aβ40-peptide. The 
measurement system was selective. Pyridoxine (vitamin B6), which is known as a neutral compound 
for  Aβ40-peptide  aggregation,  displayed  no  influence  on  this  phenomenon  when  studied  by  the 
analytical tool proposed. The obtained results showed that developed SPR-based biosensors could be 
applied  for  monitoring  of  Aβ40  aggregation  phenomena  in  real-time,  without  using  any  chemical 
markers influencing the process.  
Acknowledgements 
Presented work was supported by the Polish Ministry of Science and Higher Education—Grant  
POL-POSTDOC  III  PBZ/MNiSW/07/2006/60  and  Institute  of  Animal  Reproduction  and  Food 
Research of Polish Academy of Science, Olsztyn, Poland. 
References  
1.  Koo,  E.H.;  Lansbury,  P.T.;  Kelly,  J.W.  Amyloid  diseases:  Abnormal  protein  aggregation  in 
neurodegeneration. Proc. Natl. Acad. Sci. USA 1999, 96, 9989-9990. 
2.  Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer’s disease: Progress and problems on 
the road to therapeutics. Science 2002, 297, 353-356. 
3.  Murphy, M.P.; LeVine, H., III. Alzheimer’s disease and the amyloid-beta peptide. J. Alzheimers 
Dis. 2010, 19, 311-323. Sensors 2011, 11                                       
 
 
4040 
4.  Morgan, C.; Colombres, M.; Nuñ ez, M.T.; Inestrosa, N.C. Structure and function of amyloid in 
Alzheimer’s disease. Prog. Neurobiol. 2004, 74, 323-349. 
5.  Gsponer, J.; Vendruscolo, M. Theoretical approaches to protein aggregation. Protein Pept. Lett. 
2006, 13, 287-293. 
6.  Wang,  H.W.;  Pasternak,  J.F.;  Kuo,  H.;  Ristic,  H.;  Lambert,  M.P.;  Chromy,  B.;  Viola,  K.L.;  
Klein, W.L.; Stine, W.B.; Krafft, G.A.; Trommer, B.L. Soluble oligomers of beta amyloid (1–42) 
inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 2002, 
924, 133-140. 
7.  Levin, E.D.; McClernon, F.J.; Rezvani, A.H. Nicotinic effects on cognitive function: Behavioural 
characterization, pharmacological specification, and anatomic localization. Psychopharmacology 
(Berlin) 2006, 184, 523-539. 
8.  Emilien,  G.;  Beyreuther,  K.;  Masters,  C.L.;  Maloteaux,  J.M.  Prospects  for  pharmacological 
intervention in Alzheimer disease. Arch Neurol. 2000, 57, 454-459. 
9.  Zamani, M.R.; Allen, Y.S. Nicotine and its interaction with beta-amyloid protein: A short review. 
Biol. Psychiatry 2001, 49, 221-232. 
10.  Pogocki, D.; Ruman, T.; Danilczuk, M.; Celuch, M.; Wałajtys-Rode, E. Application of nicotine 
enantiomers,  derivatives  and  analogues  in  therapy  of  neurodegenerative  disorders.  Eur.  J. 
Pharmacol. 2007, 563, 18-39. 
11.  Salomon, A.R.; Marcinowski, K.J.; Friedland, R.P.; Zagorski, M.G. Nicotine inhibits amyloid 
formation by the beta-peptide. Biochemistry 1996, 35, 13568-13578. 
12.  Zeng, H.; Zhang, Y.; Peng, L.; Shao, H.; Menon, N.K.; Yang, J.; Salomon, A.R.; Freidland, R.P.; 
Zagorski, M.G. Nicotine and amyloid formation. Biol. Psychiatry 2001, 49, 248-257. 
13.  Moore,  S.A.;  Huckerby,  T.N.;  Gibson,  G.L.;  Fullwood,  N.J.;  Turnbull,  S.;  Tabner,  B.J.;  
El-Agnaf,  O.M.;  Allsop,  D.  Both  the  D-(+)  and  L-(–)  enantiomers  of  nicotine  inhibit  Abeta 
aggregation and cytotoxicity. Biochemistry 2004, 43, 819-826. 
14.  Ono, K.; Hasegawa, K.; Yamada, M.; Naiki, H. Nicotine breaks down preformed Alzheimer’s  
beta-amyloid fibrils in vitro. Biol. Psychiatry 2002, 52, 880-886. 
15.  Szymańska, I.; Radecka, H.; Radecki, J.; Kaliszan, R. Electrochemical impedance spectroscopy 
for  study  of  amyloid  beta-peptide  interactions  with  (–)  nicotine  ditartrate  and  (–)  cotinine. 
Biosens. Bioelectron. 2007, 22, 1955-1960. 
16.  Grabowska,  I.;  Radecka,  H.;  Burza,  A.;  Radecki,  J.;  Kaliszan,  M.;  Kaliszan,  R.  Association 
constants  of  pyridine  and  piperidine  alkaloids  to  amyloid  beta  peptide  determined  by 
electrochemical impedance spectroscopy. Curr. Alzheimer Res. 2010, 7, 165-172. 
17.  White,  D.A.;  Buell,  A.K.;  Dobson,  C.M.;  Welland,  M.E.;  Knowles  T.P.  Biosensor-based  
label-free assays of amyloid growth. FEBS Lett. 2009, 583, 2587-2592. 
18.  Aguilar,  M.I.;  Small,  D.H.  Surface  plasmon  resonance  for  the  analysis  of  beta-amyloid 
interactions and fibril formation in Alzheimer’s disease research. Neurotox. Res. 2005, 7, 17-27. 
19.  Hu,  W.P.;  Chang,  G.L.;  Chen,  S.J.;  Kuo,  Y.M.  Kinetic  analysis  of  beta-amyloid  peptide 
aggregation induced by metal ions based on surface plasmon resonance biosensing. J. Neurosci. 
Meth. 2006, 154, 190-197. 
20.  Cairo, C.W.; Strzelec, A.; Murphy, R.M.; Kiessling, L.L. Affinity-based inhibition of beta-amyloid 
toxicity. Biochemistry 2002, 41, 8620-8629. Sensors 2011, 11                                       
 
 
4041 
21.  Liu, R.; Yuan, B.; Emadi, S.; Zameer, A.; Schulz, P.; McAllister, C.; Lyubchenko, Y.; Goud, G.; 
Sierks,  M.R.  Single  chain  variable  fragments  against  beta-amyloid  (Abeta)  can  inhibit  Abeta 
aggregation and prevent abeta-induced neurotoxicity. Biochemistry 2004, 43, 6959-6967. 
22.  Lindgren,  J.;  Wahlströ m,  A.;  Danielsson,  J.;  Markova,  N.;  Ekblad,  C.;  Grä slund,  A.;  
Abrahmsé n, L.; Karlströ m, A.E.; Wä rmlä nder, S.K. N-terminal engineering of amyloid-β-binding 
affibody molecules yields improved chemical synthesis and higher binding affinity. Protein Sci. 
2010, 19, 2319-2329. 
23.  Hirohata,  M.;  Hasegawa,  K.;  Tsutsumi-Yasuhara,  S.;  Ohhashi,  Y.;  Ookoshi,  T.;  Ono,  K.;  
Yamada, M.; Naiki, H. The anti-amyloidogenic effect is exerted against Alzheimer’s beta-amyloid 
fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. 
Biochemistry 2007, 46, 1888-1899. 
24.  Ryu, J.; Joung, H.A.; Kim, M.G.; Park, C.B. Surface plasmon resonance analysis of Alzheimer’s 
beta-amyloid aggregation on a solid surface: from monomers to fully-grown fibrils. Anal Chem. 
2008, 80, 2400-2407. 
25. Wang, H.; Chen, S.; Li, L.; Jiang, S. Improved method for the preparation of carboxylic acid and 
amine terminated self-assembled monolayers of alkanethiolates. Langmuir 2005, 21, 2633-2636. 
26.  Cannon, M.J.; Williams, A.D.; Wetzel, R.; Myszka, D.G. Kinetic analysis of beta—amyloid fibril 
eleongation. Anal. Biochem. 2004, 328, 67-75. 
27.  McMasters, M.J.; Hammer, R.P.; McCarley, R.L. Surface-induced aggregation of beta amyloid 
peptide  by  -substituted  alkanethiol  monolayers  supported  on  gold.  Langmuir  2005,  21,  
4464-4470. 
28. Wang, Q.; Zhao, C.; Zhao, J.; Wang, J.; Yang, J.-C.; Yu, X.; Zheng, J. Comparative molecular 
dynamics  study  of  Aβ  adsorption  on  the  self-assembled  monolayers.  Langmuir  2010,  26,  
3308-3316. 
29. Wang, Q.; Zhao, J.; Yu, X.; Zhao, C.; Li, L.; Zheng, J. Alzheimer Aβ1–42 monomer adsorbed on  
the self-assembled monolayers. Langmuir 2010, 26, 12722-12732. 
30.  ChemSpider. Available online: http://nature.chemspider.com (accessed on 16 February 2011). 
31.  Bhal, S.K.; Kassam, K.; Peirson, I.G.; Pearl, G.M. The rule of five revisited: Applying log D in 
place of log P in drug-likeness filters. Mol. Pharm. 2007, 4, 556-560. 
32.  Ono, K.; Hasegawa, K.; Naiki, H.; Yamada, M. Curcumin has potent anti-amyloidogenic effects 
for Alzheimer’s β-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75, 742-750. 
33.  Yagi, H.; Ban, T.; Morigaki, K.; Naiki, H.; Goto, Y. Visualaization and classification of amyloid 
β supramolecular assemblies. Biochemistry 2007, 46, 15009-15017. 
34.  Zhou, N.; Chen, Z.; Zhang, D.; Li, G. Electrochemical assay of human islet amyloid polypeptide 
and its aggregation. Sensors 2008, 8, 5987-5995. 
35.  Gobbi, M.; Re, R.; Canovi, M.; Beeg, M.; Gregori, M.; Sesana, S.; Sonnino, S.; Brogioli, D.; 
Musicanti, C.; Gasco, P.; Salmona, M. Lipid-base nanoparticles with high binding affinity for 
amyloid— beta1–42 peptide. Biomaterials 2010, 31, 6519-6529. 
36.  Kremer, J.J.; Murphy, R.M. Kinetics of adsorption of Abeta(1–40) to lipid bilayers. J. Biochem. 
Biophys. Meth. 2003, 57, 159-169. Sensors 2011, 11                                       
 
 
4042 
37.  Hasegawa, K.; Ono, K.; Yamada, M.; Naiki, H. Kinetic modeling and determination of reaction 
constants of Alzheimer’s beta-amyloid fibril extension and disscociation using surface plasmon 
resonanace. Biochemistry 2002, 41, 13489-13498. 
38.  Rusnati, M.; Bugatti, A.; Mitola, S.; Leali, D.; Bergese, P.; Depero, L.E.; Presta, M. Exploiting 
surface plasmon resonance (SPR) technology for the identification of fibroblast growth factor-2 
(FGF2) anatgonists endowed with antiangiogenic activity. Sensors 2009, 9, 6471-6503. 
39.  Roh, S.; Chung, T.; Lee, B. Overview of the characteristic of micro- and nanao-structured surface 
plasmon resonanace. Sensors 2011, 11, 1565-1588. 
40.  Lee, K.-S.; Son, J.M.; Jeong, D.-Y.; Lee, T.S.; Kim, W.M. Resolution enhacement in surface 
plasmon  resonanace  sensor  based  on  waveguide  coupled  mode  by  combining  a  bimetallic 
approach. Sensors 2010, 10, 11390-11399. 
© 2011 by the authors;  licensee  MDPI, Basel, Switzerland.  This  article  is an  open access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 